Recombinant @entity1 @entity1261 ( @entity1261 ; filgrastim) shortens the time to neutrophil recovery after intensive chemotherapy, but its role in the treatment of adults with @entity981 ( @entity981 ) is uncertain. We randomly assigned 198 adults with untreated @entity981 (median age, 35 years; range, 16 to 83) to receive either placebo or @entity1261 (5 microgram/kg/d) subcutaneously, beginning 4 days after starting intensive remission induction chemotherapy and continuing until the neutrophil count was >/=1, 000/microL for 2 days. The study assignment was unblinded as individual @entity1 achieved a complete remission (CR). @entity1 initially assigned to @entity1261 then continued to receive @entity1261 through 2 monthly courses of consolidation therapy. @entity1 assigned to placebo received no further study drug. The median time to recover neutrophils >/=1,000/microL during the remission induction course was 16 days (interquartile range [IQR], 15 to 18 days) for the @entity1 assigned to receive @entity1261 and 22 days (IQR, 19 to 29 days) for the @entity1 assigned to placebo (P < .001). @entity1 in the @entity1261 group had significantly shorter durations of @entity1398 (<1, 000/microL) and @entity882 (<50,000/microL) and fewer days in the hospital (median, 22 days v 28 days; P = .02) compared with @entity1 receiving placebo. The @entity1 assigned to receive @entity1261 had a higher CR rate and fewer @entity204 during remission induction than did those receiving placebo (P = .04 by the chi-square test for trend). During Courses IIA and IIB of consolidation treatment, @entity1 in the @entity1261 group had significantly more rapid recovery of neutrophils >/=1,000/microL than did the control group by approximately 6 to 9 days. However, the @entity1 in the @entity1261 group did not complete the planned first 3 months of chemotherapy any more rapidly than did the @entity1 in the placebo group. Overall @entity137 was not lessened by the use of @entity1261 . After a median follow-up of 4. 7 years, there were no significant differences in either the disease-free survival (P = .53) or the overall survival (P = .25) for the @entity1 assigned to @entity1261 (medians, 2.3 years and 2.4 years, respectively) compared with those assigned to placebo (medians, 1.7 and 1.8 years, respectively). Adults who received intensive chemotherapy for @entity981 benefited from @entity1261 treatment, but its use did not markedly affect the ultimate outcome.

A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with XXXX : CALGB study 9111.

@entity1 :: ('9606', 'Species') :: ['Patients', 'human', 'patients'] @entity981 :: ('MESH:D054198', 'Disease') :: ['ALL', 'acute lymphoblastic leukemia'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity1261 :: ('1440', 'Gene') :: ['G-CSF', 'granulocyte colony-stimulating factor'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity204 :: ('MESH:D003643', 'Disease') :: ['deaths']
@entity981 :: (MESH:D054198,Disease) :: ['acute lymphoblastic leukemia']
